Pharmexa Pancreatic Cancer Vaccine Fails Phase III Study
This article was originally published in The Pink Sheet Daily
Executive Summary
Firm says it will continue enrolling another Phase III trial, with data expected in 2011.
You may also be interested in...
Antigenics’ Oncophage Approved In Russia, First Therapeutic Cancer Vaccine To Enter Marketplace
The biologic will launch this summer at a price in the lower range of $50,000-$100,000/patient/year, the typical cost of new cancer drugs in Russia, firm tells “The Pink Sheet” DAILY.
Dendreon Catches A Break For Provenge
Amended FDA agreement hastens IMPACT final analysis by one year.
Failed MyVax Cancer Vaccine Trial Could Be Due To Active Comparator, Genitope Says
Firm remains optimistic about the non-Hodgkin’s lymphoma vaccine due to a statistically significant increase in progression-free survival among MyVax responders.